Max Jaderberg is president of Isomorphic Labs, the drug-discovery company spun out of Google DeepMind. He previously worked as a research scientist at Google DeepMind, where his work included AlphaStar and other reinforcement-learning research.
Roles
Jaderberg leads Isomorphic Labs as its president and has become the company's primary public spokesperson on clinical readiness. Demis Hassabis serves as chief executive of both Isomorphic Labs and Google DeepMind.
Positions and statements
At WIRED Health in London on April 16, 2026, Jaderberg said the company was "gearing up to go into the clinic" with AI-designed drugs and described the internal pipeline as "broad and exciting" across oncology and immunology. He framed the design rationale around structural understanding: deeper structural insight, he argued, yields more potent molecules that can be dosed lower, reducing side effects and off-target effects (Source: wired.com).
The April 2026 timing reflects a slip from the original end-of-2025 target that Hassabis gave the Financial Times in 2024.
Relationships
- related: Isomorphic Labs — President
- related: Google DeepMind — prior employer
- related: Demis Hassabis — CEO of both Isomorphic and Google DeepMind
- related: AlphaFold, IsoDDE